About this trial
The PREEMPT trial is a multicenter randomized controlled trial comparing prophylactic onlay biosynthetic mesh reinforcement with primary suture closure in adult patients undergoing emergency midline laparotomy. Participants will be randomized in a 1:1 ratio. The primary endpoint is the incidence of incisional hernia at 1 year. Secondary endpoints include postoperative complications, surgical site occurrences, pain, operative time, hospital stay, morbidity, mortality, quality of life, and long-term hernia incidence.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Age < 18 years
Minimally invasive surgery (laparoscopic or robotic approaches)
Elective surgery
Surgery requiring an open abdomen and its closure
Trial design
Parallel
Treatments tested in this trial
Prophylactic Biosynthetic Mesh Placement
DeviceA biosynthetic mesh (poly-4-hydroxybutyrate mesh) is placed prophylactically to reinforce abdominal wall closure during laparotomy closure.
Direct suture
Procedure/SurgeryDirect fascial suture closure of the abdominal wall after laparotomy without prophylactic mesh reinforcement.
Treatment groups
Trial outcomes
Primary outcomes
Incidence of incisional hernia at 12 months after laparotomy
The primary outcome is the occurrence of incisional hernia within 12 months after laparotomy, assessed by clinical examination and/or imaging according to the study protocol. The incidence of incisional hernia will be compared between patients receiving prophylactic biosynthetic mesh reinforcement and patients undergoing standard abdominal wall closure without mesh.
Secondary outcomes
Postoperative complications
Postoperative complications will be assessed according to the Clavien-Dindo classification.
Incidence of surgical site infection
The incidence of surgical site infection (superficial, deep, and organ-space infection) occurring after laparotomy will be evaluated and compared between treatment groups
Incidence of surgical site occurrences after emergency laparotomy
The incidence of surgical site occurrences (SSO), including surgical site infection, seroma, wound dehiscence, hematoma, and other wound-related complications, will be assessed and compared between treatment groups.
Incidence of surgical site occurrences requiring procedural intervention (SSOPI)
The incidence of surgical site occurrences requiring procedural intervention (SSOPI) will be assessed. SSOPI include surgical site occurrences requiring invasive treatment, such as wound drainage, percutaneous intervention, surgical debridement, or other procedural management.
Other outcomes
Operative time
Operative time will be measured from skin incision to completion of skin closure and compared between patients undergoing prophylactic biosynthetic mesh reinforcement and patients undergoing standard abdominal wall closure.
Readmission and reoperation rates
The rates of unplanned hospital readmission and reoperation after the index surgery will be assessed and compared between treatment groups.
30-day postoperative morbidity and mortality
Thirty-day postoperative morbidity and mortality will be assessed, including the occurrence of postoperative complications and death within 30 days after the index surgery. Postoperative complications will be recorded and compared between treatment groups.
Postoperative pain assessed by Visual Analogue Scale (VAS)
Postoperative pain will be assessed using the Visual Analog Scale (VAS), a 0-10 scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores will be compared between treatment groups.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Rome Tor Vergata
Lead sponsor
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Collaborator
San Filippo Neri General Hospital
Collaborator
San Giovanni Addolorata Hospital
Collaborator
Santa Maria della Pieta Hospital - Nola
Collaborator
Buccheri La Ferla Hospital, Palermo
Collaborator
Cardarelli Hospital, Naples, Italy
Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborator
This trial is not recruiting at the moment. You can still explore other options: